Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mesoblast (MESO) Common Equity: 2015-2022

Historic Common Equity for Mesoblast (MESO) over the last 8 years, with Jun 2022 value amounting to $497.0 million.

  • Mesoblast's Common Equity fell 14.51% to $497.0 million in Q2 2022 from the same period last year, while for Jun 2022 it was $497.0 million, marking a year-over-year decrease of 14.51%. This contributed to the annual value of $497.0 million for FY2022, which is 14.51% down from last year.
  • As of FY2022, Mesoblast's Common Equity stood at $497.0 million, which was down 14.51% from $581.4 million recorded in FY2021.
  • In the past 5 years, Mesoblast's Common Equity registered a high of $581.4 million during FY2021, and its lowest value of $481.1 million during FY2019.
  • Moreover, its 3-year median value for Common Equity was $549.3 million (2020), whereas its average is $542.6 million.
  • Its Common Equity has fluctuated over the past 5 years, first rose by 14.19% in 2020, then declined by 14.51% in 2022.
  • Yearly analysis of 5 years shows Mesoblast's Common Equity stood at $546.0 million in 2018, then decreased by 11.90% to $481.1 million in 2019, then climbed by 14.19% to $549.3 million in 2020, then rose by 5.84% to $581.4 million in 2021, then declined by 14.51% to $497.0 million in 2022.